Table 1 Basic characteristics of included 3485 cancer drug trials in China
From: Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
Variables | No | % |
|---|---|---|
Study phase | ||
Phase I | 1557 | 44.7% |
Phase II | 666 | 19.1% |
Phase III | 787 | 22.6% |
Phase IV | 41 | 1.2% |
Study scope | ||
Domestic trials | 2886 | 82.8% |
International multicenter trial | 599 | 17.2% |
Sponsor typea | ||
Domestic industry | 2792 | 80.2% |
Global industry | 691 | 19.8% |
Cancer type | ||
Solid tumor | 2969 | 85.2% |
Blood tumor | 516 | 14.8% |
Drug effect | ||
Therapeutic medication | 3271 | 93.9% |
Diagnosis medication | 2 | 100.0% |
Adjuvant medication | 212 | 6.1% |
Drug type | ||
Innovative drug | 2843 | 81.6% |
Biosimilar | 134 | 3.8% |
Generics | 508 | 14.6% |
Drug molecule | ||
Chemistry medicine | 2119 | 60.8% |
Biological Products | 1333 | 38.2% |
TCM/NMb | 33 | 0.9% |